MCTA vs ACMR

For growth investors, ACM Research, Inc.

(ACMR) is the stronger pick with 15. 2% revenue growth year-over-year, versus 3. 4% for Charming Medical Limited Class A Ordinary Shares (MCTA). ACM Research, Inc. (ACMR) offers the better valuation at 43. 2x trailing P/E (29. 7x forward), making it the more compelling value choice. Analysts rate ACM Research, Inc. (ACMR) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, ACM Research, Inc.

(ACMR) is the cheapest at 43. 2x versus Charming Medical Limited Class A Ordinary Shares at 414. 5x.

Over the past 5 years, Charming Medical Limited Class A Ordinary Shares (MCTA) delivered a total return of +319.

3%, compared to +133. 4% for ACM Research, Inc. (ACMR). Over 10 years, the gap is even starker: ACMR returned +30. 7% versus MCTA's +319. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

On balance sheet safety, ACM Research, Inc.

(ACMR) carries a lower debt/equity ratio of 16% versus 24% for Charming Medical Limited Class A Ordinary Shares — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), ACM Research, Inc.

(ACMR) is pulling ahead at 15. 2% versus 3. 4% for Charming Medical Limited Class A Ordinary Shares (MCTA). On earnings-per-share growth, the picture is similar: Charming Medical Limited Class A Ordinary Shares grew EPS 54. 2% year-over-year, compared to -10. 5% for ACM Research, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Charming Medical Limited Class A Ordinary Shares (MCTA) is the more profitable company, earning 19.

3% net margin versus 10. 4% for ACM Research, Inc. — meaning it keeps 19. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MCTA leads at 22. 3% versus 12. 1% for ACMR. At the gross margin level — before operating expenses — MCTA leads at 67. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

In this comparison, ACMR (0.

2% yield) pays a dividend. MCTA does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Charming Medical Limited Class A Ordinary Shares (MCTA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+319.

3% 10Y return). ACM Research, Inc. (ACMR) carries a higher beta of 3. 24 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MCTA: +319. 3%, ACMR: +30. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (MCTA (Healthcare) and ACMR (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: MCTA is a small-cap quality compounder stock; ACMR is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.